Welcome to our dedicated page for Qualigen Therapeutics news (Ticker: QLGN), a resource for investors and traders seeking the latest updates and insights on Qualigen Therapeutics stock.
Qualigen Therapeutics Inc (QLGN) is an early clinical-stage biopharmaceutical company advancing novel cancer treatments through its investigational G-quadruplex-targeting therapies. This hub provides timely updates on corporate developments, clinical research milestones, and regulatory progress for investors and researchers.
Access press releases covering QN-302 clinical trials, preclinical program updates, financial disclosures, and strategic partnerships. Our curated news collection helps stakeholders track the company’s progress in developing precision oncology treatments while maintaining compliance with financial reporting standards.
Key updates include therapeutic pipeline advancements, peer-reviewed research publications, and material business events. All content is verified through primary sources to ensure accuracy and relevance for investment analysis and scientific evaluation.
Bookmark this page for consolidated access to Qualigen Therapeutics’ latest developments in cancer drug discovery and corporate announcements. Check regularly for authoritative updates on their innovative approach to targeting transcription mechanisms in malignant cells.
Qualigen Therapeutics announced the closing of a registered direct offering, selling 5,880,000 shares at $1.50 each, totaling $8,820,000 in gross proceeds. The offering was facilitated by A.G.P./Alliance Global Partners under an effective shelf registration statement. These funds could support the development of its therapeutic pipeline, including cancer drug candidates like QN-247 and RAS-F. However, the press release also contains forward-looking statements indicating potential risks regarding the success of drug development and regulatory approvals.
Qualigen Therapeutics (NASDAQ: QLGN) announced definitive agreements for the sale of 5,880,000 shares of common stock at $1.50 per share in a registered direct offering, expected to close around December 1, 2021. This offering is subject to conditions including a waiver from a prior investor concerning stock sale rights and warrant repricing. A.G.P./Alliance Global Partners is the sole placement agent. The transaction is part of a shelf registration statement filed with the SEC.
Qualigen Therapeutics, Inc. (Nasdaq: QLGN) reported a 38% increase in quarterly revenues to approximately $1.2 million for Q3 2021, up from $0.8 million in Q3 2020, and a 30% rise in year-to-date revenues to $4.2 million compared to $3.2 million year-over-year.
The net loss decreased to $2.9 million or $0.10 per share for Q3 2021, improved from a loss of $8.1 million or $0.41 per share in Q3 2020. Cash equivalents stand at $12.3 million, adequate for operations through late 2022.
Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announced a study validating its FastPack® IP diagnostic test for thyroid stimulating hormone (TSH) levels, published in Diagnostics. The study, with 100 participants, found FastPack comparable to traditional lab methods, offering results in about 15 minutes versus a 2-day wait. This validates FastPack's accuracy in real-world settings, enhancing its market position. Since its inception, FastPack sales have surpassed $100 million, demonstrating its established role in diagnostics for various conditions.
Qualigen Therapeutics, Inc. (NASDAQ: QLGN) announced that CEO Michael Poirier will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit from September 20-23, 2021. The presentation, scheduled for September 22 at 4:35 pm EDT, will focus on the company's oncology drug pipeline, particularly QN-247 and RAS-F, which have shown promising preclinical results. The virtual format allows for one-on-one meetings with management and will be available for live viewing and for 90 days after.
Qualigen Therapeutics, Inc. (NASDAQ: QLGN) will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. CEO Michael Poirier will discuss the company’s oncology pipeline, including promising preclinical results for QN-247 and RAS-F assets. The presentation will be available virtually starting September 13 at 7:00 AM ET and accessible for 90 days. Virtual one-on-one meetings with management will be held during the conference. Qualigen focuses on cancer therapies with potential Orphan Drug Designation and also has a diagnostics division.
Qualigen Therapeutics (Nasdaq: QLGN) shifts focus to its oncology pipeline, including QN-247 and RAS-F, after receiving FDA feedback on its COVID-19 candidate, QN-165. The FDA requested more preclinical studies, prompting the pivot due to the crowded market. Q2 revenue rose 24% to $1.1 million, while the first half saw a 28% increase to $3.0 million. Net loss for Q2 was $5.3 million, down from $18.6 million in 2020. Cash equivalents stood at $15.2 million as of June 30, 2021. Qualigen aims to secure Orphan Drug status for QN-247, enhancing its market position in oncology.
Qualigen Therapeutics (NASDAQ: QLGN) announces the submission of an Investigational New Drug (IND) application for QN-165 to the FDA, targeting COVID-19 treatment in hospitalized patients. QN-165 is a DNA aptamer designed to block viral replication by binding to the nucleolin protein. Chairman and CEO Michael Poirier expressed excitement over this milestone, emphasizing QN-165's unique mechanism that may protect against various virus strains. This marks a significant shift for Qualigen from diagnostics to therapeutics, enhancing its clinical-stage program.
Qualigen Therapeutics (NASDAQ: QLGN) will be added to the Russell Microcap Index at the end of the annual reconstitution on June 28, 2021. This membership signifies progress in its oncology and viral disease pipeline. Membership also ensures automatic inclusion in relevant growth and value indexes, which are significant for institutional investors managing approximately $10.6 trillion in assets. Qualigen's CEO, Michael Poirier, expressed excitement over this milestone, highlighting its implications for investment and growth opportunities.
Qualigen Therapeutics (NASDAQ: QLGN) announced CEO Michael Poirier will present at the LD Micro Invitational XI Conference from June 8-10, 2021. The presentation is scheduled for June 9, 2021, at 12:30 pm PT (3:30 pm ET) in Track 4. It will highlight the company’s therapeutics pipeline aimed at addressing significant unmet needs in cancer and viral diseases, along with the established FastPack® diagnostics line. Attendees can request virtual one-on-one meetings with management.
FAQ
What is the current stock price of Qualigen Therapeutics (QLGN)?
What is the market cap of Qualigen Therapeutics (QLGN)?
